HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of early and delayed ischemic postconditioning enhances brain-derived neurotrophic factor production by upregulating the ERK-CREB pathway in rats with focal ischemia.

Abstract
Ischemic postconditioning, including early and delayed ischemic postconditioning, has been recognized as a simple and promising strategy in the treatment of stroke. However, the effects of the combination of early and delayed ischemic postconditioning, and the mechanisms underlying these effects, remain unclear. The aim of the present study was to determine whether the combination of early and delayed ischemic postconditioning offers greater protection against stroke, and enhances the production of brain‑derived neurotrophic factor (BDNF). A combination of early and delayed ischemic postconditioning was established by repeated, transient occlusion and reperfusion of the ipsilateral common carotid artery in a rat model of middle cerebral artery occlusion. Infarct size, motor function, cerebral blood flow and brain edema were then evaluated, in order to confirm the effects of combinative ischemic postconditioning. TUNEL staining was used to analyze the rate of apoptosis of cells in the penumbral area. BDNF, extracellular signal‑regulated kinases 1/2 (ERK1/2) and cAMP response element‑binding protein (CREB) expression was detected using immunofluorescence staining and western blot analysis. The results of the present study indicated that the combination of early and delayed ischemic postconditioning further reduced the infarct volume, stabilized cerebral blood disturbance and attenuated neuronal apoptosis, compared with either alone. However, combinative postconditioning exerted the same effect on neurological function and brain edema, compared with early or delayed ischemic postconditioning alone. Further investigation indicated that combinative ischemic postconditioning increased the expression of BDNF, and a significantly higher number of BDNF‑positive cells was observed in neurons and astrocytes from the combined group than in the early or delayed groups. Combinative ischemic postconditioning also induced the phosphorylation of ERK1/2 and CREB in the cortex, following focal ischemia. The results of the present study suggest that the combination of early and delayed ischemic postconditioning may further reduce brain ischemic reperfusion injury following focal ischemia, compared with either treatment alone. In addition, it induces the production of BDNF in neurons and astrocytes. Furthermore, the effects of combinative ischemic postconditioning may be mediated by the activation of ERK1/2 and CREB.
AuthorsHui Wu, Shao-Feng Yang, Jiong Dai, Yong-Ming Qiu, Yi-Feng Miao, Xiao-Hua Zhang
JournalMolecular medicine reports (Mol Med Rep) Vol. 12 Issue 5 Pg. 6427-34 (Nov 2015) ISSN: 1791-3004 [Electronic] Greece
PMID26398857 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Brain-Derived Neurotrophic Factor
  • Cyclic AMP Response Element-Binding Protein
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
Topics
  • Animals
  • Apoptosis
  • Astrocytes (metabolism, pathology)
  • Brain Edema (etiology, genetics, pathology, therapy)
  • Brain Ischemia (etiology, genetics, pathology, therapy)
  • Brain-Derived Neurotrophic Factor (genetics, metabolism)
  • Cerebral Cortex (metabolism, pathology)
  • Cyclic AMP Response Element-Binding Protein (genetics, metabolism)
  • Gene Expression Regulation
  • Infarction, Middle Cerebral Artery (complications, surgery)
  • Ischemic Postconditioning (methods)
  • MAP Kinase Signaling System
  • Male
  • Mitogen-Activated Protein Kinase 1 (genetics, metabolism)
  • Mitogen-Activated Protein Kinase 3 (genetics, metabolism)
  • Neurons (metabolism, pathology)
  • Rats
  • Rats, Sprague-Dawley
  • Stroke (etiology, genetics, pathology, therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: